AMGN vs SKYE · P/E 24, rev $10.05B vs $25.0M cap
Amgen Inc (AMGN) versus Skye Bioscience, Inc. Common Stock (SKYE) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
SKYE does not have a complete income-statement cache yet.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. SKYE currently screens at market cap $25.0M.
Not investment advice. Open the AMGN and SKYE stock pages for the full models.
Not investment advice.